Pharma Intelligence is part of the Informa Intelligence Division of Informa PLC
This is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
73 Total results for product and free and sample content found
Biomedtracker, Datamonitor Healthcare
By Daniel Chancellor 06 Aug 2019
With arguably the standout data from the 2019 American Society for Clinical Oncology (ASCO) annual meeting, Amgen has become the first company to show that KRAS, beyond its role as an oncogene, is also a viable drug target
Topic BioPharmaceutical Drug review
Datamonitor Healthcare, Pharmaprojects, Biome...
By Daniel Chancellor 03 Jul 2019
In previous years, delegates at the American Society for Clinical Oncology (ASCO) annual meeting had been treated to exciting clinical data from anti-CD19 chimeric antigen receptor T-cell (CAR-T) therapies such as Kymriah (tisagenlecleucel; Novartis), Yescarta (axicabtagene ciloleucel; Gilead), and various pipeline assets in advanced hematologic malignancies.
Topic Cancer Cell and gene therapy
Trialtrove
By Laura Runkel 02 Jul 2019
The geographic scope of industry sponsored clinical trial activities has gone global. Successful programs require putting all the pieces together to ensure efficient enrollment of the target patients at high quality facilities to reliably execute detailed study protocols. Myriad differences between countries, including disease epidemiology, standard of care options, and logistical factors around medical facilities and practices, create challenges to making the right geographic choices.
Topic Clinical trials
Skipta, Citeline
By Pamela Spicer 15 Jun 2019
Skipta, the leading social network of specialized online medical communities for verified healthcare professionals, recently hosted a virtual advisory board session, through its proprietary Skipta Gather technology, asking physicians what they saw as the current unmet needs in the treatment of rheumatoid arthritis (RA).
Topic Arthritis
Datamonitor Healthcare
By Daniel Chancellor 11 Jun 2019
In April, immuno-oncology (IO) celebrated its ninth birthday, following the approval of Provenge, the first drug that harnesses the body’s immune system to fight cancer, in April 2010. Since this landmark event, it has been a tremendous decade for the field, with IO becoming part of the standard-of-care in a range of treatment settings and the Nobel Prize being awarded for the discovery of immune checkpoint inhibition. It is the checkpoint inhibitor drug classes that are leading the IO revolution and will act as a foundation for the next decade of oncology research. This article reviews the childhood years of IO and predicts what the future may hold as it reaches double digits and matures through adolescence.
Topic Cancer
Pharma Consulting
By Duncan Emerton 10 Jun 2019
What’s the boggle with biologics? If there is one fact that even the most casual observer of the pharma industry is aware of, it is that biologics are the leading growth engine of global medicines spending. Revenues from biologics increased by 70% during 2011–16 to reach $232bn, accounting for roughly 20–22% of total pharmaceutical spending.
Topic Biosimilars
Strategic Transactions
By Daniel Chancellor 23 May 2019
PharmAI – industry is smartening up to the potential of artificial intelligence
Datamonitor Healthcare
By Charlotte Huntley 13 May 2019
Cystic fibrosis is an inherited disease characterized by frequent respiratory infections Cystic fibrosis (CF) is an inherited disease affecting water retention, most notably causing patients to produce large amounts of thick mucus. This mucus blocks up the lungs and digestive system and is difficult to clear. People with CF commonly and frequently suffer from respiratory infections, resulting in scarring of their airways.
Trialtrove
By Judy Adair 01 May 2019
There’s a song running through my head as I reflect on April being Parkinson’s Disease (PD) Awareness month. It’s Kool & The Gang’s hit from 1980, Celebration. In case you don’t recall, it started, “There’s a party goin’ on right here. A celebration to last throughout the years…”, with the refrain, “Come on now…Celebration…Let’s all celebrate and have a good time!”. Now why, you might ask, would anyone want to celebrate Parkinson’s? You’re right, but it’s not the disease I’m celebrating. I’m celebrating the people who fight Parkinson’s Disease day in and day out. I’m referring to those who suffer from the disease, their family members, caretakers, and the researchers working for a cure or symptom relief.
Topic Parkinsons disease Diseases
No Records Found
Request a live demo
Getting a demo tailored to your needs is the best way to see how our solutions will help you gain an advantage.
Request live demo now:
How can we help you?
Our team is always happy to hear from you. Please call us at:
Pharma Report Store
Have an immediate and specific information need?
Browse and buy from 1000s of analysis and research reports now:
